RU2015131033A - Вакцины с повышенной плотностью размещения углеводного антигена и новый сапониновый адъювант - Google Patents
Вакцины с повышенной плотностью размещения углеводного антигена и новый сапониновый адъювант Download PDFInfo
- Publication number
- RU2015131033A RU2015131033A RU2015131033A RU2015131033A RU2015131033A RU 2015131033 A RU2015131033 A RU 2015131033A RU 2015131033 A RU2015131033 A RU 2015131033A RU 2015131033 A RU2015131033 A RU 2015131033A RU 2015131033 A RU2015131033 A RU 2015131033A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- vaccine according
- vaccine
- carbohydrate antigen
- toxoid
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims 17
- 239000000427 antigen Substances 0.000 title claims 7
- 102000036639 antigens Human genes 0.000 title claims 7
- 108091007433 antigens Proteins 0.000 title claims 7
- 150000001720 carbohydrates Chemical class 0.000 title claims 7
- 239000002671 adjuvant Substances 0.000 title claims 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 title claims 4
- 229930182490 saponin Natural products 0.000 title claims 4
- 150000007949 saponins Chemical class 0.000 title claims 4
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 8
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 claims 3
- 229960000814 tetanus toxoid Drugs 0.000 claims 3
- 239000000463 material Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- SGNXVBOIDPPRJJ-PSASIEDQSA-N 1-[(1r,6r)-9-azabicyclo[4.2.1]non-4-en-5-yl]ethanone Chemical compound CC(=O)C1=CCC[C@@H]2CC[C@H]1N2 SGNXVBOIDPPRJJ-PSASIEDQSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims 1
- 108010034055 CRM45 fragment of diphtheria toxin Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 239000003948 anatoxin Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229960003983 diphtheria toxoid Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000004228 ovarian endometrial cancer Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/256—Polyterpene radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Virology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (24)
1. Вакцина, содержащая
(a) углеводный антиген или его иммуногенный фрагмент и
(b) белок-анатоксин,
где соотношение углеводного антигена к белку-анатоксину находится в диапазоне от 5:1 до 39:1.
2. Вакцина по п. 1, где белок-анатоксин представляет собой дифтерийный токсин (DT).
3. Вакцина по п. 2, где соотношение углеводного антигена к DT находится в диапазоне от 8:1 до 24:1.
4. Вакцина по п. 1, где белок-анатоксин представляет собой столбнячный анатоксин (ТТ).
5. Вакцина по п. 4, где соотношение углеводного антигена к ТТ находится в диапазоне от 7:1 до 12:1.
6. Вакцина по п. 1, где углеводный антиген выбран из Globo Н, SSEA-3, SSEA-4 или Gb-4.
7. Вакцина по п. 6, где углеводный антиген представляет собой Globo Н.
8. Вакцина по п. 2, где DT представляет собой материал, перекрестно реагирующий с дифтерийным токсином, или дифтерийный анатоксин.
9. Вакцина по п. 8, где материал, перекрестно реагирующий с дифтерийным токсином, выбран из CRM30, CRM45, CRM 176, CRM 197 или CRM 228.
10. Вакцина по п. 1, дополнительно содержащая сапониновый адъювант.
11. Вакцина по п. 10, где сапониновый адъювант представляет собой сапонин OBI-821.
12. Вакцина по п. 1, дополнительно содержащая адъювант α-галактозил-церамид (α-GalCer).
13. Вакцина по п. 12, где адъювант α-GalCer характеризуется следующей структурой:
14. Фармацевтическая композиция, содержащая
(a) вакцину по п. 1 и
(b) фармацевтически приемлемый носитель
15. Фармацевтическая композиция по п. 14, где белок-анатоксин из вакцины по п. 1 представляет собой дифтерийный токсин (DT).
16. Способ ингибирования раковых клеток, включающий введение эффективного количества вакцины по п. 1 субъекту, нуждающемуся в этом, где раковые клетки ингибируются.
17. Способ по п. 16, где рак представляет собой рак, экспрессирующий Globo Н.
18. Способ по п. 17, где рак, экспрессирующий Globo Н, представляет собой рак молочной железы, рак легкого, рак желудка, рак толстой кишки, рак поджелудочной железы, рак предстательной железы, рак яичника и рак эндометрия.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361748880P | 2013-01-04 | 2013-01-04 | |
| US61/748,880 | 2013-01-04 | ||
| PCT/US2014/010310 WO2014107652A2 (en) | 2013-01-04 | 2014-01-06 | Vaccines with higher carbohydrate antigen density and novel saponin adjuvant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015131033A true RU2015131033A (ru) | 2017-02-09 |
Family
ID=51062556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015131033A RU2015131033A (ru) | 2013-01-04 | 2014-01-06 | Вакцины с повышенной плотностью размещения углеводного антигена и новый сапониновый адъювант |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10517936B2 (ru) |
| EP (2) | EP2941436B1 (ru) |
| JP (2) | JP6359561B2 (ru) |
| KR (2) | KR101806370B1 (ru) |
| CN (2) | CN111499679B (ru) |
| AU (2) | AU2014203977B2 (ru) |
| CA (2) | CA3044471C (ru) |
| CL (2) | CL2015001900A1 (ru) |
| ES (1) | ES2843509T3 (ru) |
| IL (2) | IL239785B (ru) |
| PH (1) | PH12015501519A1 (ru) |
| RU (1) | RU2015131033A (ru) |
| SG (1) | SG11201505301XA (ru) |
| TW (2) | TWI572356B (ru) |
| WO (1) | WO2014107652A2 (ru) |
| ZA (1) | ZA201504813B (ru) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2843509T3 (es) | 2013-01-04 | 2021-07-19 | Obi Pharma Inc | Vacunas con mayor densidad de antígeno carbohidratado y nuevo adyuvante de saponina |
| AU2014391422A1 (en) | 2013-09-17 | 2015-12-17 | Obi Pharma, Inc. | Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment |
| US9828436B2 (en) | 2014-03-19 | 2017-11-28 | Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital | Antibodies against immunogenic glycopeptides, compositions comprising the same and use thereof |
| WO2016040369A2 (en) * | 2014-09-08 | 2016-03-17 | Academia Sinica | HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS |
| CA2961522A1 (en) * | 2014-09-15 | 2016-03-24 | Obi Pharma, Inc. | Immunogenic/therapeutic glycoconjugate compositions and uses thereof |
| US20170348414A1 (en) * | 2014-09-15 | 2017-12-07 | Wayne State University | Novel synthetic anticancer, antifungal, and antibacterial vaccines |
| KR20180050339A (ko) | 2015-09-04 | 2018-05-14 | 오비아이 파머 인코퍼레이티드 | 글리칸 어레이 및 사용 방법 |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| KR20180121786A (ko) | 2016-03-29 | 2018-11-08 | 오비아이 파머 인코퍼레이티드 | 항체, 제약 조성물 및 방법 |
| SG11201809024UA (en) | 2016-04-22 | 2018-11-29 | Obi Pharma Inc | Cancer immunotherapy by immune activation or immune modulation via globo series antigens |
| TWI752988B (zh) | 2016-07-27 | 2022-01-21 | 台灣浩鼎生技股份有限公司 | 免疫性/治療性聚醣組合物及其用途 |
| EP3491026A4 (en) | 2016-07-29 | 2020-07-29 | OBI Pharma, Inc. | HUMAN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND PROCESSES |
| CN110290800A (zh) | 2016-11-21 | 2019-09-27 | 台湾浩鼎生技股份有限公司 | 缀合生物分子、医药组合物及方法 |
| US20210396759A1 (en) * | 2018-05-11 | 2021-12-23 | Obi Pharma, Inc. | Method for Predicting Human Immune Response |
| TW202504930A (zh) | 2018-06-27 | 2025-02-01 | 台灣浩鼎生技股份有限公司 | 用於糖蛋白工程的糖苷合成酶變體及其使用方法 |
| CN114805454B (zh) * | 2021-01-21 | 2023-07-18 | 中国科学院生态环境研究中心 | α-半乳糖神经酰胺类化合物及其制备方法和用途 |
| CN114259559B (zh) * | 2021-12-28 | 2024-03-19 | 天津科技大学 | 一种含有α-GalCer内源性佐剂的合成肿瘤疫苗 |
| CN114306586A (zh) * | 2022-01-04 | 2022-04-12 | 天津科技大学 | 基于tf抗原和壳寡糖内源性佐剂的肿瘤疫苗、方法和应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| GB8727489D0 (en) | 1987-11-24 | 1987-12-23 | Connaught Lab | Detoxification of pertussis toxin |
| US5332583A (en) | 1987-11-24 | 1994-07-26 | Connaught Laboratories Limited | Vaccine containing genetically-detoxified pertussis holotoxin |
| US5244657A (en) | 1987-11-24 | 1993-09-14 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
| US5358868A (en) | 1987-11-24 | 1994-10-25 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
| US5221618A (en) | 1987-11-24 | 1993-06-22 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
| ES2231770T3 (es) | 1993-03-05 | 2005-05-16 | Wyeth Holdings Corporation | Nuevos plasmidos para la produccion de proteina crm y toxina difterica. |
| US6544952B1 (en) | 1994-03-15 | 2003-04-08 | Sloan-Kettering Institute For Cancer Research | Synthesis of glycoconjugates of the globo-H epitope and uses thereof |
| HUP9802199A3 (en) * | 1995-06-07 | 1999-07-28 | Smithkline Beecham Biolog | Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein and use of |
| PL323863A1 (en) * | 1995-06-23 | 1998-04-27 | Smithkline Beecham Biolog | Vaccine containing a conjugate of polysaccharidic antigen with proteinous carrier and free proteinous carrier |
| US6231859B1 (en) | 1996-12-02 | 2001-05-15 | Aquila Biopharmaceuticals, Inc. | Saponin adjuvant compositions |
| US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| IL132886A0 (en) | 1997-05-20 | 2001-03-19 | Galenica Pharmaceuticals Inc | A triterpene saponin-lipophile conjugate a pharmaceutical composition containing the same and a vaccine containing the same |
| US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
| DE10130545A1 (de) | 2001-06-25 | 2003-01-09 | Bosch Gmbh Robert | Verfahren zum Betrieb einer Klimaanlage |
| AU2002354804A1 (en) | 2001-07-06 | 2003-01-21 | Sloan-Kettering Institute For Cancer Research | Polyvalent conjugate vaccine for cancer |
| AU2002357359B2 (en) * | 2001-12-21 | 2009-01-08 | Csl Limited | Compositions comprising immunoreactive reagents and saponins, and methods of use thereof |
| US20060035267A1 (en) | 2003-04-09 | 2006-02-16 | Livingston Philip O | Optimal polyvalent vaccine for cancer |
| CA2531023C (en) | 2003-07-04 | 2013-04-30 | Institut Pasteur | Glycoconjugates and their use as potential vaccines against infection by shigella flexneri |
| GB0323965D0 (en) * | 2003-10-13 | 2003-11-19 | Glaxosmithkline Biolog Sa | Immunogenic compositions |
| WO2006084050A2 (en) | 2005-02-01 | 2006-08-10 | Dyax Corp. | Libraries and methods for isolating antibodies |
| JP2010523724A (ja) | 2007-04-13 | 2010-07-15 | アカデミア シニカ | α−ガラクトシルセラミド類似体およびそれらの免疫療法剤としての使用 |
| US8324742B2 (en) * | 2008-04-01 | 2012-12-04 | Texas Instruments Incorporated | Alignment mark for opaque layer |
| JP5706815B2 (ja) | 2008-04-08 | 2015-04-22 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | トリテルペンであるサポニン、その合成法および使用 |
| WO2010005735A2 (en) * | 2008-06-16 | 2010-01-14 | Academia Sinica | Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment |
| US7928077B2 (en) | 2008-07-11 | 2011-04-19 | Academia Sinica | Alpha-galactosyl ceramide analogs and their use as immunotherapies |
| CN102215862B (zh) * | 2009-06-16 | 2016-04-06 | 中央研究院 | Globo h及含新颖糖脂质佐剂的相关抗癌疫苗 |
| CN103108654A (zh) | 2010-06-11 | 2013-05-15 | 索隆-基特林癌症研究协会 | 多价糖肽构建体及其用途 |
| EP2827903A4 (en) | 2012-03-23 | 2016-02-10 | Sloan Kettering Inst Cancer | POTENTIATION OF ANTIBODY-INDUCED COMPLEMENT-MEDIATED CYTOTOXICITY BY PI3K INHIBITION |
| ES2843509T3 (es) | 2013-01-04 | 2021-07-19 | Obi Pharma Inc | Vacunas con mayor densidad de antígeno carbohidratado y nuevo adyuvante de saponina |
| ITMI20130142A1 (it) | 2013-01-31 | 2014-08-01 | Biosynth Srl | Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati |
| CN104693305A (zh) | 2013-12-04 | 2015-06-10 | 苏州中赢医疗科技有限公司 | 一种抗人鞘糖脂Globo-H单克隆抗体、其制备方法及应用 |
-
2014
- 2014-01-06 ES ES14735355T patent/ES2843509T3/es active Active
- 2014-01-06 TW TW103100353A patent/TWI572356B/zh active
- 2014-01-06 CN CN202010234884.2A patent/CN111499679B/zh active Active
- 2014-01-06 SG SG11201505301XA patent/SG11201505301XA/en unknown
- 2014-01-06 EP EP14735355.1A patent/EP2941436B1/en active Active
- 2014-01-06 JP JP2015551806A patent/JP6359561B2/ja active Active
- 2014-01-06 KR KR1020157020818A patent/KR101806370B1/ko active Active
- 2014-01-06 CN CN201480003725.4A patent/CN105026413B/zh active Active
- 2014-01-06 RU RU2015131033A patent/RU2015131033A/ru not_active Application Discontinuation
- 2014-01-06 CA CA3044471A patent/CA3044471C/en active Active
- 2014-01-06 WO PCT/US2014/010310 patent/WO2014107652A2/en not_active Ceased
- 2014-01-06 EP EP20187437.7A patent/EP3792272A1/en active Pending
- 2014-01-06 CA CA2897084A patent/CA2897084C/en active Active
- 2014-01-06 AU AU2014203977A patent/AU2014203977B2/en active Active
- 2014-01-06 KR KR1020177034329A patent/KR102084301B1/ko active Active
- 2014-01-06 US US14/758,319 patent/US10517936B2/en active Active
- 2014-01-06 TW TW105141502A patent/TWI611810B/zh active
-
2015
- 2015-07-03 CL CL2015001900A patent/CL2015001900A1/es unknown
- 2015-07-03 ZA ZA2015/04813A patent/ZA201504813B/en unknown
- 2015-07-03 PH PH12015501519A patent/PH12015501519A1/en unknown
- 2015-07-03 CL CL2015001902A patent/CL2015001902A1/es unknown
- 2015-07-05 IL IL239785A patent/IL239785B/en active IP Right Grant
-
2017
- 2017-01-17 AU AU2017200312A patent/AU2017200312B2/en active Active
-
2018
- 2018-04-16 IL IL258728A patent/IL258728B/en active IP Right Grant
- 2018-06-20 JP JP2018117319A patent/JP6781204B2/ja active Active
-
2019
- 2019-11-01 US US16/671,395 patent/US11752204B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015131033A (ru) | Вакцины с повышенной плотностью размещения углеводного антигена и новый сапониновый адъювант | |
| PH12017500484A1 (en) | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers | |
| PH12019501552A1 (en) | Polypeptide-antigen conjugates with non-natural amino acids | |
| CR20160018A (es) | Nueva inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (nsclc) | |
| MX2018001421A (es) | Peptidos y combinacion de peptidos para usarse en la inmunoterapia contra el cancer de prostata y otros tipos de cancer. | |
| MX2019014829A (es) | Vacunas de conjugado multivalente con polisacáridos de conjugado bivalente o multivalente que proporcionan inmunogenicidad y avidez mejoradas. | |
| MX2018005273A (es) | Peptidos y combinacion de peptidos para usarse en la inmunoterapia contra el cancer de mama y otos tipos de cancer. | |
| PH12021551208A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| NZ734197A (en) | Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers | |
| MX2016007865A (es) | Peptidos citotoxicos y conjugados de los mismos. | |
| MX2017017145A (es) | Peptidos novedosos y combinacion de peptidos para usarse en inmunoterapia contra cancer de ovario y otros canceres. | |
| CR20220115A (es) | PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS NOVEDOSOS PARA SU USO EN INMUNOTERAPIA CONTRA DIVERSOS TUMORES (Div. 2017-522) | |
| MX2017001638A (es) | Molecula portadora para antigenos. | |
| EA202090319A1 (ru) | Пептидные конъюгаты, способ конъюгации и их использование | |
| MY190083A (en) | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers | |
| MX2020011791A (es) | Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer. | |
| AR051494A1 (es) | Formulaciones inmunoterapeuticas para la induccion de autoanticuerpos bloqueadores de la union de interleucina -2 a su receptor , su uso en el tratamiento del cancer | |
| WO2014186596A8 (en) | Correlates of efficacy relating to tumor vaccines | |
| NZ770913A (en) | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers | |
| AR108308A1 (es) | Inmunoterapia para cáncer mediante activación inmunológica o modulación inmunológica a través de antígenos de la serie globo | |
| TH126648A (th) | Ect2 เปปไทด์ และ วัคซีนที่รวมถึงสิ่งเดียวกันนั้น | |
| MY198397A (en) | Novel Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer | |
| EA202090821A1 (ru) | Новый метод иммунотерапии нескольких видов опухолей, таких как рак легкого, включая нмрл |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170619 |